Boost Brittle Bones Before Birth

Exclusion Criteria

• •1. Existence of other known disorder that might interfere with the treatment, such as, but not limited to organ dysfunction (for example liver or renal failure or bronchopulmonary dysplasia), congenital heart defect, hypoxic encephalopathy l-lll, severe neurological problems, immune deficiencies, muscle diseases, severe malformations or syndromes diagnosed by clinical examination.
• •2. Any contraindication for invasive procedures such as a moderate/severe bleeding tendency
• •3. Known risk factors for clotting, such as, but not limited to previous blood clot, family history of clots, clotting disorder (inherited or acquired), heart failure, inflammatory disorders (for example lupus, rheumatoid arthritis, inflammatory bowel disease)
• •4. Positive Donor Specific Antibody-test
• •5. Known allergy/hypersensitivity to Fungizone and/or Gensumycin
• •6. Abnormal karyotype or other confirmed genetic syndromes
• •7. Oncologic disease (previous or current malignancy)
• •8. Inability to comply with the trial protocol and follow-up schedule
• •9. Inability to understand the information and to provide informed consent
• •1. Multiple pregnancy
• •2. Co-existence of other disorder that might interfere with the treatment, as judged by the Investigator or the patient's obstetrician
• •3. Abnormal fetal karyotype or other confirmed genetic syndrome
• •4. Any contraindication for invasive procedures such as a bleeding tendency or contagious infections, such as, but not limited to HIV, Syphilis, Hepatitis B, Hepatitis C or other known infectious diseases that can harm the fetus
• •5. Known risk factors for clotting, such as, but not limited to previous blood clot, family history of clots, clotting disorder (inherited or acquired), heart failure, inflammatory disorders (for example lupus, rheumatoid arthritis, inflammatory bowel disease)
• •6. Positive Donor Specific Antibody-test
• •7. Known allergy/hypersensitivity to Fungizone and/or Gensumycin
• •8. Oncologic disease in woman or fetus (previous or current malignancy)
• •9. Unwilling to or cannot undergo delivery by elective Caesarean section
• •10. Inability to comply with the trial protocol and follow-up schedule
• •11. Inability to understand the information and to provide informed consent
• •1. Existence of other disorder that might interfere with the trial. No lung hypoplasia (type II OI).
• •2. Abnormal karyotype